{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:50:12Z","timestamp":1782305412663,"version":"3.54.5"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Clin Oncol"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1038\/s41571-026-01154-x","type":"journal-article","created":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T08:03:16Z","timestamp":1776931396000},"page":"471-472","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Did ATOMIC really improve on the standard of care for mismatch\u00a0repair-deficient colon cancer?"],"prefix":"10.1038","volume":"23","author":[{"given":"Javier-David","family":"Benitez-Fuentes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deme","family":"Karikios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7444-8594","authenticated-orcid":false,"given":"Bishal","family":"Gyawali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"1154_CR1","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1056\/NEJMoa2507874","volume":"394","author":"FA Sinicrope","year":"2026","unstructured":"Sinicrope, F. A. et al. Atezolizumab plus FOLFOX for stage III mismatch repair-deficient colon cancer. N. Engl. J. Med. 394, 1155\u20131166 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR2","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1200\/JCO.20.01762","volume":"39","author":"B Gyawali","year":"2021","unstructured":"Gyawali, B. & West, H. J. Lessons from ADAURA on adjuvant cancer drug trials: evidence, ethics, and economics. J. Clin. Oncol. 39, 175\u2013177 (2021).","journal-title":"J. Clin. Oncol."},{"key":"1154_CR3","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.1016\/S1470-2045(20)30527-1","volume":"21","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 21, 1620\u20131629 (2020).","journal-title":"Lancet Oncol."},{"key":"1154_CR4","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1200\/JCO.2005.01.6071","volume":"23","author":"DJ Sargent","year":"2005","unstructured":"Sargent, D. J. et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J. Clin. Oncol. 23, 8664\u20138670 (2005).","journal-title":"J. Clin. Oncol."},{"key":"1154_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1016\/j.annonc.2019.12.007","volume":"31","author":"ME Salem","year":"2020","unstructured":"Salem, M. E. et al. Evaluation of the change of outcomes over a 10-year period in patients with stage III colon cancer: pooled analysis of 6501 patients treated with fluorouracil, leucovorin, and oxaliplatin in the ACCENT database. Ann. Oncol. 31, 480\u2013486 (2020).","journal-title":"Ann. Oncol."},{"key":"1154_CR6","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9, T. et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N. Engl. J. Med. 383, 2207\u20132218 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR7","doi-asserted-by":"publisher","first-page":"e80","DOI":"10.1016\/S1470-2045(24)00451-0","volume":"26","author":"B Gyawali","year":"2025","unstructured":"Gyawali, B. et al. Common sense oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials. Lancet Oncol. 26, e80\u2013e89 (2025).","journal-title":"Lancet Oncol."},{"key":"1154_CR8","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41571-023-00857-9","volume":"21","author":"GW Strohbehn","year":"2024","unstructured":"Strohbehn, G. W. & Gyawali, B. \u2018Contribution of component\u2019 and the perioperative immune-checkpoint inhibitor precedent. Nat. Rev. Clin. Oncol. 21, 249\u2013250 (2024).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1154_CR9","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","volume":"390","author":"M Chalabi","year":"2024","unstructured":"Chalabi, M. et al. Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer. N. Engl. J. Med. 390, 1949\u20131958 (2024).","journal-title":"N. Engl. J. Med."},{"key":"1154_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf322","author":"B Gyawali","year":"2025","unstructured":"Gyawali, B. De-escalation trials do not always need to be non-inferiority: a case for superiority design de-escalation trials in oncology. J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djaf322 (2025).","journal-title":"J. Natl. Cancer Inst."}],"container-title":["Nature Reviews Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01154-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01154-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01154-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T12:02:28Z","timestamp":1782302548000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41571-026-01154-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":10,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1154"],"URL":"https:\/\/doi.org\/10.1038\/s41571-026-01154-x","relation":{},"ISSN":["1759-4774","1759-4782"],"issn-type":[{"value":"1759-4774","type":"print"},{"value":"1759-4782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]},"assertion":[{"value":"23 April 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.-D.B.-F. declares no competing interests. B.G. has acted as a consultant of Vivio Health. D.K. has acted as an advisor of Lutris, MSD, Roche and Takeda, and has received speaker\u2019s fees from Abbvie and AstraZeneca.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}